Quantitative analysis for ICON Public Limited Company (ICLR) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Buy (58.0) (grade B). 32 signals analyzed (27 differentiated alt-data).
ICLR stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $119.43 | $110.38 | $116.17 |
| 2026-05-11 | $124.80 | $120.71 | $121.17 |
| 2026-05-21 | $116.80 | $112.43 | $116.57 |
| 2026-06-03 | $145.92 | $135.52 | $143.90 |
| 2026-06-15 | $148.74 | $144.84 | $147.72 |
| 2026-06-26 | $170.50 | $158.59 | $169.86 |
| 2026-07-09 | $170.40 | $164.42 | $168.77 |
| 2026-07-21 | $167.64 | $162.18 | $166.62 |
| 2026-07-31 | $170.24 | $162.40 | $163.57 |
| 2026-08-12 | $167.74 | $161.77 | $167.17 |
| 2026-08-24 | $174.44 | $168.38 | $173.48 |
| 2026-09-03 | $164.35 | $159.55 | $163.58 |
How ICON Public Limited Company stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| ABVX | Abivax S.A. | $7.9B | — |
| GRFS | Grifols, S.A. | $6.9B | — |
| RDY | Dr. Reddy's Laboratories Limited | $11.3B | — |
| FMS | Fresenius Medical Care AG & Co. KGaA | $12.0B | — |
View all Health Care stocks by valuation and signals →
ICON Public Limited Company (ICLR) scores Buy (58.0), and the composite conceals a 50-point disagreement between its dimensions. It is strongest on technicals at 72, and weakest on analyst consensus at 38 and competitive moat at 22. A stock can carry technicals that high while competitive moat sits at 22; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| technicals | 72 |
| valuation | 46 |
| earnings quality | 39 |
| analyst consensus | 38 |
| competitive moat | 22 |
StoQuant analyzes 32 signals (27 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on ICON Public Limited Company (ICLR): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/ICLR"><img src="https://stoquant.com/badge/ICLR.svg" alt="ICON Public Limited Company (ICLR) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.